Relationships between KRAS mutation status and baseline radiographic distribution of disease in patients with stage IV colorectal cancer

被引：0
|
作者：
Michael H. Rosenthal
Kyung Won Kim
Charles S. Fuchs
Jeffrey A. Meyerhardt
Nikhil H. Ramaiya
机构：
[1] Dana-Farber Cancer Institute,Department of Imaging
[2] Brigham Women’s Hospital,Department of Radiology
[3] University of Ulsan College of Medicine,Department of Radiology, Asan Medical Center
[4] Dana-Farber Cancer Institute,Department of Medical Oncology
[5] Harvard Medical School,undefined
来源：
Abdominal Imaging | 2014年 / 39卷
关键词：
Colorectal cancer; Diagnostic imaging; KRAS oncogenes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1261 / 1266
页数：5
相关论文
共 50 条
  • [31] Association between autophagy and KRAS mutation with clinicopathological variables in colorectal cancer patients
    Awi, Noel Jacques
    Yap, Hooi-Yeen
    Armon, Subasri
    Low, John Seng-Hooi
    Peh, Kaik-Boo
    Peh, Suat-Cheng
    Lee, C. Soon
    Teow, Sin-Yeang
    MALAYSIAN JOURNAL OF PATHOLOGY, 2021, 43 (02) : 269 - 279
  • [32] Association between KRAS mutation and alcohol consumption in Brazilian patients with colorectal cancer
    Bianca Gomes-Fernandes
    Luísa Martins Trindade
    Marcela de Castro Bastos Rodrigues
    João Pedro Duarte Cardoso
    Frederico Temponi Lima
    Luíza Rogerio
    Simone de Vasconcelos Generoso
    Juliana Garcia Carneiro
    Rodrigo Gomes da Silva
    Renan Pedra de Souza
    Luiz De Marco
    Luciana Bastos-Rodrigues
    Scientific Reports, 14 (1)
  • [33] Relationships among KRAS mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer
    Xiang-Bin Wan
    Ai-Qin Wang
    Jian Cao
    Zhi-Chuang Dong
    Ning Li
    Sen Yang
    Miao-Miao Sun
    Zhi Li
    Su-Xia Luo
    World Journal of Gastroenterology, 2019, (07) : 808 - 823
  • [34] Relationships among KRAS mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer
    Wan, Xiang-Bin
    Wang, Ai-Qin
    Cao, Jian
    Dong, Zhi-Chuang
    Li, Ning
    Yang, Sen
    Sun, Miao-Miao
    Li, Zhi
    Luo, Su-Xia
    WORLD JOURNAL OF GASTROENTEROLOGY, 2019, 25 (07) : 808 - 823
  • [35] Comparison of KRAS Mutation Tests in Colorectal Cancer Patients
    Hancer, Veysel Sabri
    Buyukdogan, Murat
    Turkmen, Ilknur
    Bassullu, Nuray
    Altug, Tuncay
    Diz-Kucukkaya, Reyhan
    Bulbul-Dogusoy, Gulen
    Demir, Gokhan
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2011, 15 (11) : 831 - 834
  • [36] Prognostic factors of survival in stage IV colorectal cancer with synchronous liver metastasis: Negative effect of the KRAS mutation
    Diez-Alonso, Manuel
    Mendoza-Moreno, Fernando
    Jimenez-Alvarez, Laura
    Nunez, Oscar
    Blazquez-Martin, Alma
    Sanchez-Gollarte, Ana
    Matias-Garcia, Belen
    Molina, Raquel
    San-Juan, Alberto
    Gutierrez-Calvo, Alberto
    MOLECULAR AND CLINICAL ONCOLOGY, 2021, 14 (05)
  • [37] Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
    Mekenkamp, Leonie J. M.
    Tol, Jolien
    Dijkstra, Jeroen R.
    de Krijger, Inge
    Vink-Borger, M. Elisa
    van Vliet, Shannon
    Teerenstra, Steven
    Kamping, Eveline
    Verwiel, Eugene
    Koopman, Miriam
    Meijer, Gerrit A.
    van Krieken, J. Han J. M.
    Kuiper, Roland
    Punt, Cornelis J. A.
    Nagtegaal, Iris D.
    BMC CANCER, 2012, 12
  • [38] KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
    Lievre, A.
    Bachet, J.
    Boige, V
    Landi, B.
    Emile, J.
    Cote, J.
    Tomasic, G.
    Rougier, P.
    Penault-Llorca, F.
    Laurent-Puig, P.
    ANNALS OF ONCOLOGY, 2006, 17 : 42 - 42
  • [39] Kras mutation status as biomarker for response to TRAIL treatment in colorectal cancer
    Van Schaeybroeck, Sandra
    Kyula, Joan
    Longley, Dan
    Johnston, Patrick
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [40] Metabolic factors and the risk of colorectal cancer by KRAS and BRAF mutation status
    Myte, Robin
    Gylling, Bjorn
    Haggstrom, Jenny
    Haggstrom, Christel
    Zingmark, Carl
    Burstrom, Anna Lofgren
    Palmqvist, Richard
    Van Guelpen, Bethany
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (02) : 327 - 337
12345